Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults (determined by medical history, physical examination, and clinical judgment)~* HIV uninfected~* Female participants of child bearing potential must have a negative serum β-human chorionic gonadotrophin pregnancy test at the screening visit and immediately prior to each vaccine/placebo administration, practice adequate birth control measures from 28 days prior to the first vaccine/placebo administration through to at least 3 months after the final vaccine/placebo administration~* Male participants who are sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a double barrier method of birth control, e.g. either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository~Exclusion Criteria:~* Confirmed HIV-1/-2 infection~* Chronic active hepatitis B or hepatitis C or active syphilis infection. Active syphilis documented by exam or serology unless positive serology is due to past treated infection~* Within the 12 months prior to enrollment: a history of newly acquired syphilis, gonorrhea, non-gonococcal urethritis, herpes simplex virus type 2 (HSV2), Chlamydia, pelvic inflammatory disease (PID), trichomonas, mucopurulent cervicitis, epididymitis, proctitis, lymphogranulomavenereum, chancroid, or hepatitis B~* A woman who is breastfeeding~* Any clinically significant acute or chronic medical condition that, in the opinion of the investigator, would preclude participation~* Major surgery within the 4 weeks prior to study entry or planned major surgery through the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Group 1- MVA Mosaic (Type: EXPERIMENTAL): Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered Modified Vaccinia Ankara (MVA) Mosaic at Week 0 and at Week 12.
- Group 2 - Placebo (Type: PLACEBO_COMPARATOR): Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
- Group 3 - MVA Mosaic (Type: EXPERIMENTAL): Healthy volunteers previously vaccinated with Ad26.ENVA.01 will be administered MVA Mosaic at Week 0 and at Week 12.
- Group 4- Placebo (Type: PLACEBO_COMPARATOR): Participants previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).